Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Eastern Cooperative Oncology Group
NRG Oncology
Institut Cancerologie de l'Ouest
M.D. Anderson Cancer Center
Brigham and Women's Hospital
Stanford University
Filamon LTD
Aminex Therapeutics, Inc.
Hoffmann-La Roche
Psyence Australia Pty Ltd
ViroMissile, Inc.
Hummingbird Bioscience
Replimune Inc.
Dana-Farber Cancer Institute
Kaiser Permanente
Mayo Clinic
University of Florida
Tizona Therapeutics, Inc
Essen Biotech
Essen Biotech
Sapience Therapeutics
MacroGenics
Daiichi Sankyo
M.D. Anderson Cancer Center
Second Life Therapeutics
Fusion Pharmaceuticals Inc.
University of Southern California
The Netherlands Cancer Institute
OncoNano Medicine, Inc.
Ohio State University Comprehensive Cancer Center
Mayo Clinic
The First Affiliated Hospital of Xinxiang Medical College
Abramson Cancer Center at Penn Medicine
AstraZeneca
Bayer
Tempus AI
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
Virginia Commonwealth University
Hadassah Medical Organization
British Columbia Cancer Agency
Institut Curie
Washington University School of Medicine
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.